Fig. 1From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAverage change from baseline best-corrected visual acuity (BCVA) at each time point; BCVA values are displayed in -Log MAR scale; M0: Baseline, M1: Month 1; M3: Month 3; M6: Month 6; M12: Month 12 of followupBack to article page